Time to treatment and survival in triple negative breast cancer patients receiving trimodality treatment in the United States. (2018)

• Record Type: Journal Article
• Authors: Larson, K.E.; Grobmyer, S.R.; Karafa, M.; Pratt, D.
• Is Part Of: Cancer treatment and research communications. Number 16(2018)
• Page Start: 32
• Page End: 37
• Publication Date: 2018
• DOI: 10.1016/j.ctarc.2018.04.002
• Languages: English
• ISSNs: 2468-2942

Abstract

Abstract: Background: Time from diagnosis to treatment for breast cancer patients has been linked to outcomes. Our goal was to assess the relationship between survival, time to first treatment (TFT), and time to treatment completion (TTC) in Stage I-III triple negative breast cancer (TNBC) receiving trimodality therapy (surgery, chemotherapy, and radiation). Methods: National Cancer Database (NCDB) was queried for TNBC patients diagnosed with Stage I-III disease from 2010 to 2011 who received all treatments (surgery, chemotherapy, radiation) within 18 months of diagnosis. Multivariate analysis controlled for age, stage, operation, neoadjuvant chemotherapy (NAC), and comorbidities. Results: 17, 717 women were included. Most had early stage disease (34.1% Stage 1; 48.2% Stage 2) treated with lumpectomy (69.2%) and adjuvant chemotherapy (63.3%). During follow-up (2.8 ± 1.1 years), mortality was 11.4%. TFT was 34.8 days for NAC and 35.6 days for surgery. Multivariate analysis demonstrated no mortality difference when considering TFT in 30 day ( p = 0.43) or 6 week ( p = 0.91) intervals. When separating into NAC or surgery first, there remained no mortality difference when considering TFT in 30 day (NAC p = 0.96, surgery p = 0.26) or 6 week (NAC p = 0.91, surgery p = 0.91) intervals. Overall, TTC was 9.0 ± 1.8 months. When dividing patients into tertiles by TTC, multivariate analysis demonstrated no survival difference between groups ( p = 0.9). There was also no mortality difference for each 30 day increased TTC ( p = 0.40). Conclusions: In Stage I-III TNBC patients receiving trimodality therapy, TFT (NAC or surgery) and TTC do not impact short-term survival if TTC is <18 months.